article
Stem Cell In-Depth Focus 2019
This in-depth focus looks at the modification of stem cells to facilitate their efficient delivery to tumours, highlighting the new development of pluripotent stem cells.
List view / Grid view
Immunotherapy
news
Update on the development of new novel cancer immunotherapy
The SCIB2 vaccine is to to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial.
webinar
A high-throughput approach to developing T-cell immunotherapies
23 May 2019 | By Sartorius
Join us as we discuss the promises and pitfalls associated with developing individualised antigen-specific T-cell therapy products for clinical use.
news
Artificial chemical receptor developed to assist in T cell engineering
Engineered T cell immunotherapy (such as chimeric antigen receptor T cell (CAR-T) and T cell receptor T cell (TCR-T) therapy), could potentially be used as a therapeutic strategy for tumour treatment.
news
Single-cell sequencing reveals landscape of immune cell subtypes in lung cancer tumours
Researchers have used single-cell sequencing to map the landscape of myeloid cells in tumours from patients with lung cancer...
news
Counteracting T-cell exhaustion in CAR-T cancer therapies
Engineered T-cells that target NFAT and Nr4a proteins could help to prevent the exhaustion of T-cells during CAR-T immunotherapy...
news
Immunotherapy and DNA damage repair combo could target lung cancer
Combination therapy with a CHK1 or PARP inhibitor, with an immune checkpoint inhibitor caused the regression of small cell lung cancer in all mice treated...
news
Sartorius Stedim Biotech introduces BIOSTAT® RM TX with Flexsafe® RM TX for producing consistent quality cellular products
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry announced the launch of the BIOSTAT® RM TX single-use bioreactor, a new wave mixed system developed specifically for closed, automated expansion of consistent quality cell products such as ex vivo cellular immunotherapies...
product
Intellicyt® T Cell Activation Cell and Cytokine Profiling Kit
17 January 2019 | By IntelliCyt, a Sartorius Company
Multiplexed approach to measure T-cell activation, proliferation and quantify cytokine release in a single well
article
Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
news
New approach turns immune cells into tiny anti-tumour drug factories
In lab and mouse experiments researchers have developed a method to leverage B cells to manufacture and secrete tumour-suppressing microRNAs...
article
Self-delivering RNAi: paving the way for a new class of cancer immunotherapies
Earlier this year, the National Cancer Institute published its annual report to the nation on the status of cancer stating that there will be nearly 1.8 million new cases of cancer in 2018.1 New therapies have developed over time to improve cancer patient outcomes, including antibody immunotherapies targeting immune checkpoints,…
news
War On Cancer 2018: targeted therapies in oncology
War On Cancer 2018 discussed how cancer treatments have evolved over the last few decades, and looked at the future of cancer therapies...
news
RIP1 kinase as a therapeutic target for pancreatic cancer
RIP1 has been shown to suppress the action of macrophages against the immune system and could be a potential therapeutic target for pancreatic cancer...
news
Scientists test new anti-PD-L1 cancer vaccine against melanoma
An experimental cancer vaccine that boosts the immune system's ability to fight cancers could work in tandem with other cancer therapies to fight aggressive tumours, scientists have reported...
